Extra drug after Chemo-Radiation: can it keep esophageal cancer at bay?
NCT ID NCT07246330
Summary
This study is for people with advanced esophageal cancer that cannot be removed by surgery. After patients complete standard chemotherapy, immunotherapy, and radiation without their cancer getting worse, this trial tests if adding more of the immunotherapy drug toripalimab helps control the cancer longer compared to just watching it. About 340 participants will be randomly assigned to either receive the extra drug for up to a year or be closely monitored without it.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.